Famotidine
Pepcid
Histamine-2 Receptor Antagonist
NADAC/unit
$0.0303
No Shortage
Tier 1: 159.6%
34 Manufacturers
63 ANDAs
indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease....
vs. brand Pepcid: Generic saves up to 100% per unit
Market Intelligence
2025-12-03 Class I Recall: Fresenius Kabi USA, LLC
2023-07-26 Class II Recall: Glenmark Therapeutics, Inc.
Generic Manufacturers
AJANTA PHARMA LTDALEMBIC PHARMACEUTICALS LTDALKEM LABORATORIES LTDAMNEAL PHARMACEUTICALS LLCANNORA PHARMA PRIVATE LTDASCENT PHARMACEUTICALS INCAUROBINDO PHARMA LTDBAXTER HEALTHCARE CORPCARLSBAD TECHNOLOGY INCCARNEGIE PHARMACEUTICALS LLCCHARTWELL RX SCIENCES LLCCONTRACT PHARMACAL CORPDR REDDYS LABORATORIES LTDEPIC PHARMA LLCFRESENIUS KABI USA LLCHIKMA PHARMACEUTICALS USA INCIVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USALANNETT CO INCLUPIN LTDMANKIND PHARMA LTDMICRO LABS LTDMSN LABORATORIES PRIVATE LTDMYLAN LABORATORIES LTDNAVINTA LLCNOVEL LABORATORIES INCNOVITIUM PHARMA LLCREGCON HOLDINGS LLCRISING PHARMA HOLDING INCRISING PHARMA HOLDINGS INCSAGENT PHARMACEUTICALSSOMERSET THERAPEUTICS LLCUNICHEM LABORATORIES LTDVKT PHARMA PRIVATE LTDZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.